This is the authors' abstract. We don't add key points for this paper.
Prostate-specific membrane antigen (PSMA) PET imaging has been recognized as an effective modality for early and accurate prostate cancer (PCa) diagnosis. While the 18 F-labeled PSMA tracer was initially approved for clinical use, the structure–activity relationship (SAR) has been underexplored due to limited accessibility of the tracers. Herein, we designed and synthesized a group of PSMA PET tracers through structure-based meticulous optimization for potential interactions at the amphipathic S1 site. Notably, the 18 F-fluorinated electron-neutral and -rich aryl moiety instead was incorporated into the KuE motif through direct photocatalyzed 18 F-deoxyfluorination. The preferred [ 18 F] 1c (SUV max = 11.40 ± 1.75) demonstrated significantly superior tumor uptake over the clinically used [ 18 F] DCFPyL (SUV max = 1.49 ± 0.31) and [ 68 Ga] PSMA-11 (SUV max = 4.2 ± 0.35) in LNCaP mice model and exhibited favorable metabolic properties. Moreover, the [ 18 F] 1c was successfully produced on a commercial autosynthesis module and further evaluated on a rhesus macaque, which holds great potential for clinical transformation of PCa diagnosis.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: